Two-dimensional transcriptome profiling: Identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4079-4088

  Li, Hai Ri ^a,f   Wang Rodriguez, Jessica ^b   Nair, T Murlidharan ^g   Yeakley, Joanne M ^e   Kwon, Young Soo ^a   Bibikova, Marina ^e   Zheng, Christina ^a,d   Zhou, Lixin ^e   Zhang, Kui ^a   Downs, Tracy ^c   Fu, Xiang Dong ^a   Fan, Jian Bing ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ILLUMINA INC   (United States)

^f MUDANJIANG MEDICAL UNIVERSITY   (China)

^g INDIANA UNIVERSITY SOUTH BEND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; MESSENGER RNA; PARAFFIN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RNA ANALYSIS; RNA SPLICING; RNA STABILITY; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; TUMOR CLASSIFICATION;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33646240135     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4264     Document Type: Article

References (51)

1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97:3133-275.
2. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer data base. Cancer 2003;98:1169-78.
3. Thompson I, Leach RJ, Pollock BH, Naylor SL. Prostate cancer and prostate-specific antigen: the more we know, the less we understand. J Natl Cancer Inst 2003;95:1027-8.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
5. Shen-Ong GL, Feng Y, Troyer DA. Expression profiling identifies a novel α-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res 2003;63:3296-301.
6. Stearns ME, Wang M, Hu Y, Kim G, Garcia FU. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Δ773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest 2004;84:785-95.
7. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65: 5761-8.
8. Johnson JM, Castle J, Garrett-Engele P, et al. Genomewide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302:2141-4.
9. Sorek R, Shamir R, Ast G. How prevalent is functional alternative splicing in the human genome? Trends Genet 2004;20:68-71.
10. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and non-sense-mediated mRNA decay in humans. Proc Natl Acad Sci U S A 2003;100:189-92.
11. Green RE, Lewis BP, Hillman RT, et al. Widespread predicted nonsense-mediated mRNA decay of alternatively-spliced transcripts of human normal and disease genes. Bioinformatics 2003;19 Suppl 1:i118-21.
12. Maniatis T, Reed R. An extensive network of coupling among gene expression machines. Nature 2002;416:499-506.
13. Maquat LE. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004;5:89-99.
14. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004;37:584-94.
15. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
16. Yeakley JM, Fan JB, Doucet D, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002;20:353-8.
17. Clark TA, Sugnet CW, Ares MJ. Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 2002;296:907-10.
18. Le K, Mitsouras K, Roy M, et al. Detecting tissue-specific regulation of alternative splicing as a qualitative change in microarray data. Nucleic Acids Res 2004;32:e180.
19. Pan Q, Shai O, Misquitta C, et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol Cell 2004;16:929-41.
20. Ule J, Ule A, Spencer J, et al. Nova regulates brain-specific splicing to shape the synapse. Nat Genet 2005;37:844-52.
21. Fan JB, Yeakley JM, Bibikova M, et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 2004;14:878-85.
22. Bibikova M, Talantov D, Chudin E, et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004;165:1799-807.
23. Cramer P, Caceres JF, Cazalla D, et al. Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol Cell 1999;4:251-8.
24. Cramer P, Pesce CG, Baralle FE, Kornblihtt AR. Functional association between promoter structure and transcript alternative splicing. Proc Natl Acad Sci U S A 1997;94:11456-60.
25. de la Mata M, Alonso CR, Kadener S, et al. A slow RNA polymerase II affects alternative splicing in vivo. Mol Cell 2003;12:525-32.
26. Auboeuf D, Dowhan DH, Kang YK, et al. Differential recruitment of nuclear receptor co-activators may determine alternative RNA splice site choice in target genes. Proc Natl Acad Sci U S A 2004;101:2270-4.
27. Auboeuf D, Dowhan DH, Li X, et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol Cell Biol 2004;24:442-53.
28. Auboeuf D, Honig A, Berget SM, O'Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002;298:416-9.
29. Walt DR. Techview: molecular biology. Bead-based fiber-optic arrays. Science 2000;287:451-2.
30. Fan JB, Oliphant A, Shen R, et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003;68:69-78.
31. Gunderson KL, Kruglyak S, Graige MS, et al. Decoding randomly ordered DNA arrays. Genome Res 2004;14:870-7.
32. Galinsky VL. Automatic registration of microarray images. II. Hexagonal grid. Bioinformatics 2003;19:1832-6.
33. Workman C, Jensen LJ, Jarmer H, et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 2002;3:RESEARCH0048(1-16).
34. Cleveland W. Robust locally weighted regression and smoothing scatter plots. J Am Stat Assoc 1979;74:829-36.
35. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
36. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
37. Stuart RO, Wachsman W, Berry CC, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A 2004;101:615-20.
38. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
39. Lara PN, Jr., Kung HJ, Gumerlock PH, Meyers FJ. Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol 1999;32:197-208.
40. Zheng CL, Kwon YS, Li HR, et al. MAASE: an alternative splicing database designed for supporting splicing microarray applications. RNA 2005;11:1767-76.
41. Zheng CL, Fu XD, Gribskov M. Characteristics and regulatory elements defining constitutive splicing and different modes of alternative splicing in human and mouse. RNA 2005;11:1777-87.
42. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215-23.
43. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002;420:691-5.
44. Schadt EE, Li C, Su C, Wong WH. Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem 2000;80:192-202.
45. Ein-Dor L, Kela I, Getz G, Givol O, Domany E. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005;21:171-8.
46. Zha S, Ferdinandusse S, Denis S, et al. α-Methylacyl-CoA racemose as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003;63:7365-76.
47. Mubiru JN, Shen-Ong GL, Valente AJ, Troyer DA. Alternative spliced variants of the α-methylacyl-CoA racemase gene and their expression in prostate cancer. Gene 2004;327:89-98.
48. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87.
49. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
50. Kornblihtt AR, de la Mata M, Fededa JP, Munoz MJ, Nogues G. Multiple links between transcription and splicing. RNA 2004;10:1489-98.
51. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.